Delivery Order SPE2DR25D2014-SPE2DR26FZ73C
- Not listed
- The Defense Logistics Agency has awarded a delivery order valued at $37,827.70 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. This competitively awarded, firm fixed price contract involves no set-aside designation and carries an ultimate completion date of November 18, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a leading...
- The Defense Logistics Agency awarded a $8,586.16 delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials, with completion targeted for July 31, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and is performed out of the contractor's Conshohocken, Pennsylvania location. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $18,471.46 to AmerisourceBergen Drug Corp on October 20, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. This is a firm fixed-price, non-set-aside contract with performance expected at the vendor's facility in Conshohocken, Pennsylvania, and an ultimate completion date of October 21, 2025. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) designated SPE2DX with...
- The Defense Logistics Agency awarded a $15,421.05 delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. The contract employs firm fixed pricing with no set-aside designation and an ultimate completion date of July 29, 2025. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The IDC serves as a...
- The Defense Logistics Agency awarded a delivery order valued at $3,759.96 to AmerisourceBergen Drug Corp for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials. This competitive award utilizes a firm fixed-price contract type with an ultimate completion date of September 10, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order valued at $1,906.70 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. The contract was awarded on September 22, 2025, with an ultimate completion date of September 23, 2025, and employs firm fixed price pricing with no set-aside designation. The place of performance is listed as AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $14,891.23 delivery order to AmerisourceBergen Drug Corp for Ozempic 2 mg/dose (8 mg/3 ml) 3 ml vials, with a completion date of November 13, 2025. This competitively awarded, firm fixed-price delivery order represents a single pharmaceutical product requisition under the agency's medical supply procurement operations. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This...
- The Defense Logistics Agency awarded a delivery order valued at $37,515.43 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. This firm fixed-price contract, awarded on June 6, 2025, with an ultimate completion date of June 9, 2025, represents a non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The work will be performed at the company's corporate headquarters in...
- The Defense Logistics Agency awarded a delivery order valued at $7,450.02 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. The contract, which was competitively awarded without set-aside provisions, carries a firm fixed price structure with an ultimate completion date of August 18, 2025. Performance will be executed from AmerisourceBergen's location in Conshohocken, Pennsylvania, the company's corporate headquarters. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $7,386.04 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. This is a firm fixed price, non-set-aside contract with an ultimate completion date of September 26, 2025, and represents performance at the vendor's Conshohocken, Pennsylvania facility. The delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- SPE2DR25D2014Indefinite Delivery Contract
- SPE2DR25D2014-SPE2DR26FZ73CDelivery Order
The Defense Logistics Agency awarded a $19,743.30 delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. The contract was awarded on November 17, 2025, with an ultimate completion date of November 18, 2025, using firm fixed price pricing with no set-aside designation. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $1 billion and extends through December 2026. The IDC serves as a comprehensive pharmaceutical supply vehicle enabling the company to provide a wide range of medications and medical supplies to support military healthcare programs globally. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement. The company supplies brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's performance under the billion-dollar IDC demonstrates its capability to meet federal procurement requirements through open competition and positions it as a key supplier for military and veteran healthcare needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $19.7k | 11/17/25 |